Rapid immunoassays are widely used to screen for amphetamine abuse. Broad spectrum immunoassays are the most useful for this purpose followed by physicochemical techniques for verification and identification of particular drugs. We describe the production of an antiserum with a broad specificity for the amphetamine group of drugs. The antiserum was produced in a sheep using an immunogen linking amphetamine to keyhole limpet haemocyanin via an N-aminobutyl bridge. This antiserum was used to develop a fluorescence polarization immunoassay for application to urine samples. A limited investigation into the use of saliva as an alternative sample was also performed. The effects of chemical modifications to the basic amphetamine structure on antibody binding are discussed.
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Amphetamine and many of its analogues ( Fig. 1 ) have been commonly abused for many years. The analogues of importance include methylamphetamine and, to a lesser extent, ephedrine and phentermine. Furthermore, the recent popularity of methylene-dioxymethylamphetamine ('ecstasy') and the increasing use of free base methylamphetamine ('ice') make their detection essential in any screening programme. Clinical laboratories now screen large numbers of samples for these compounds and require analytical techniques with a high throughput for initial screening, followed by positive identification with techniques such as gas liquid chromatography (GLC).'*' Immunoassays are widely used for screening because of their ease of automation and rapid turnover. Those based on fluorescence polarization' are relatively simple and hence are often preferred.
Varying the structure of an immunogen to expose different chemical groups to the immune system allows development of assays with differing ~pecificities.~ We originally developed specific assays5v6 to complement the broad-specificity commercial assays that were available at the time and preferred to mix our antisera to broaden their appli~ation.'.~ However, there is a need for Correspondence: Mr G J Turner.
broad-spectrum antisera for screening purposes and this work describes the development of an antiserum which recognizes the amphetamines as a group.
MATERIALS AND METHODS
D-amphetamine sulphate, DL-methylamphetamine hydrochloride, phentermine hydrochloride, ephedrine hydrochloride, phenylpropanolamine hydrochloride, fenfluramine hydrochloride, diethylpropion hydrochloride, methylenedioxymethylamphetamine (MDMA), methylenedioxyamphetamine (MDA), l-ethyl-3-(3-dimethylaminopropyl) carbodiimide and fluorescein isothiocyanate isomer 1 were obtained from Sigma (Poole, UK). Mephentermine was kindly donated by the Poisons Unit, New Cross (London, UK). Keyhole Limpet Haemocyanin (Calbiochem) was from Cambridge BioScience (Cambridge, UK). mephentermine, ephedrine, phenylpropanolamine, fenfluramine, diethylpropion, MDA and MDMA were prepared in methanol. These stock solutions were diluted in assay buffer to give concentrations of 0.5, 1.0, 2.0, 5-0, 10, 20, and 100mg/L.
Preparation of N-butylamine derivatives
These were prepared by a modification of the method of Cheng et aL9 Amphetamine free base (6 g) and N-(4-aminobutyl)phthalimide (12 g) were dissolved in 100mL dried ethanol and refluxed for 24 h. After cooling, hydrazine hydrate (1.8 mL) was added and refluxing was continued for 2 h. After cooling, the solution was evaporated to a small volume and adjusted to p H 2 with 0.5 M HCI. The resulting precipitate was filtered, the clear filtrate adjusted to pH 10 with 1 M NaOH and extracted five times with 50 mL ethyl acetate (the aqueous phase was readjusted to pH 10 after each extraction). The ethyl acetate was removed by evaporation, leaving a strawcoloured viscous liquid which was purified by thin layer chromatography (TLC) (ethyl acetate/ methanol/ammonia; 85: 10:5). The product (R, 0.38) gave a single peak by GLC and was confirmed as N-(4-aminobutyl) amphetamine by nuclear magnetic resonance (20% yield; 98% pure). The N-(4-aminobutyl) derivative of methylamphetamine was similarly prepared.
Preparation of fluorescent tracers
Fluorescein isothiocyanate (32 mg, 80 pnol) was dissolved in 2 m L methanol containing 0.1 mL triethylamine. N-(4-aminobutyl)-amphetamine (18 mg, 80 pmol) was added and mixed for 4 h. The mixture was applied to a preparative TLC plate and the chromatogram developed using chloroform/methanol (5050). An intense band at R , 0.6 was eluted into methanol. A tracer was also prepared using N-(4-aminobutyl)methylamphetamine by the same procedure which gave an intense band at Rr 0.5. and keyhole limpet haemocyanin (100 mg) were dissolved in a mixture of 10mL water and 2 mL pyridine. l-Ethyl-3-(3dimethylaminopropyl) carbodiimide hydrochloride (1 66 mg, 860 pmol) was added in 8 aliquots at hourly intervals, the reaction mixture was stirred for 2 days and then dialysed for 5 days (3 L distilled water, changed daily). The resulting suspension was concentrated to less than 1 mL, then made up to 5 mL with sterile saline giving a protein concentration of 20 mg/mL.
Preparation of immunogen

Immunization
Four mature female sheep were immunized following a previously described protocoI.l0 Antiserum from a bleed taken 6 weeks after the initial immunization was used in the assay development.
Patient specimens
Known negative urines and saliva samples were supplied by staff volunteers. Positive saliva samples were supplied by staff undergoing medication with either phentermine, phenylpropanolamine, or ephedrine. Other samples were obtained from patients attending a drug dependency clinic.
Equipment
A Model PF120 polarization fluonmeter (Perkin-Elmer, Beaconsfield, UK), or the TDxTM fluorescence polarization analyser (Abbott Laboratories, Maidenhead, UK) were used.
Procedures
PoIarization fluoroimmunoassay using the PF120
T o 0-5 mL of a 30 nmol/L tracer solution was added lOpL of urine or 1OOpL saliva, or the equivalent amount of standard. Antiserum was diluted 250-fold in assay buffer and 1 mL diluted antiserum was added, the reactants were mixed and polarization readings were taken after 15 min incubation at room temperature.
Final concentrations in the test solution were thus: tracer 10 nmol/L, antiserum dilution 1/375.
Polarization fluoroimmunoassay using the TDx
As the analyser dilutes reagents 80-fold the antiserum was placed in the reagent containers diluted 10-fold. Tracer was used at 240 nmol/L alld the sample volume was set at IOpL. Final dilution for the antiserum was therefore 1/800 and final tracer concentration was 3 nmol/L.
Gas-liquid chromatography
This was carried out using a Hewlett-Packard 5890A (Hewlett-Packard, Winnersh, UK), fitted with an HP2 capillary column (25 mm x 0.32 mm ID, 0 17 mm film thickness) a split injector and nitrogen detector, with a model 7673A autosampler and model 3390A integrator.
RESULTS
Standard curves
The antiserum gave similar titres with both tracers but slightly better sensitivity, for the majority of analogues, with the methylamphetamine derived tracer which was used for further assay development. Figure 2 shows the standard curve.
Assay sensitivity
Twenty replicates of a zero standard (assay buffer) were assayed using the TDx. The minimum detectable dose at 95% confidence level" was 0.06 mg/L. The within-batch coefficients of variation (CVs) using standards containing 1, 5 , and 10mg/L were 6.3'70, 2.1'70, and 3.0%, respectively. Between-batch CVs were 8.3'70, 3 .5%, and 4 -2 % , respectively. The minimum detectable dose using the PF120 was 0 -2 mg/L using a 10 pL sample for urines and Amphetamine concentration (mg/LI 0.04 mg/L using a 100 pL sample for saliva. The PF120 proved less precise, giving within batch CVs of 22'70, 14%, and 9.470, and was not used for urine assay validation.
Detection limit with urine and saliva samples
Twenty drug-free urines and saliva were assayed. The cut-off level was set at three standard deviations above the mean (0-6 mg/L for amphetamine in urine on the TDx). Since salivary assays required a large sample volume, these samples were only assayed on the PF120 and gave a cut-off of 0.1 mg/L for amphetamine. A single dose of 25 mg phentermine was detectable in both saliva and urine for 7 2 h whereas a 25 mg dose of phenylpropanolamine was only detectable for 2 h in saliva but for 48 h in urine. One volunteer took 18mg ephedrine which proved detectable for at least 24 h in both saliva and urine.
Cross-reactivity studies
Standard curves were assayed using the methylamphetamine tracer and cross reactivities were calculated.I2 The derivative used for the immunogen was expected to stimulate the production of antibodies that recognize methylamphetamine better than amphetamine. Cross-reactivities were therefore set at 100% using methylamphetamine standards (Table 1) . However, amphetamine standards are used for routine assays (Fig. 2) . The only interferent which would give a positive result at therapeutic concentrations using the 0.6 mg/L cut-off was the beta blocking agent, labetalol which cross-reacted 80% when compared to amphetamine.
TAni t. 1 . Cross reuclivities of compounds structurully reluted to amohetamine (methylamphetamine = 100%)
Cross reactivity to non-amphetamine compounds
Interference from other compounds was checked by assaying non-amphetamine drugs and catecholamine precursors and metabolites (amphetamine resembles the catecholamines and interferes with their action^).'^ The following showed less than 1 Vo cross reactivity at concentrations of 1 g/L:
Acebutolol, adrenaline, amitriptyline, amylobarbitone, atenolol, benzoylecgonine, betaxolol, bupivacaine, butobarbitone, caffeine, carbamazepine, chlordiazepoxide, chlorpromazine, clomipramine, cocaine, codeine, cyclobarbitone, desipramine, desmethylclomipramine, desmethyldothiepin, desmethyldoxepin, desmethylmianserin, dextromethorphan, dextromoramide, diacetalol, diazepam, dihydrocodeine, dipipanone, dothiepin, doxepin, glutethimide, hexobarbitone, imipramine, lignocaine, maprotiline, meprobamate, methadone, methylphenobarbitone, methyprylone, metoprolol, mianserin, morphine, nadolol, naloxone, nortriptyline, oxazepam, oxprenolol, paracetamol, penbutolol, pentazocine, pentobarbitone, pethidine, phencyclidine, phenobarbitone, phenytoin, pholcodine, pindolol, primidone, propoxyphene, quinidine, salicyclic acid, secobarbitone, sotalol, temazepam, thioridazine, timolol, trifluoperazine.
Correlation with existing GLC method
Twenty negative urines and 46 samples positive by GLC for any of amphetamine, methylamphetamine, phentermine, fenfluramine, diethylpropion, ephedrine, phenylpropanolamine, or MDMA were tested. No false negatives were found. One sample found to have 0 . 5 mg/L of amphetamine by GLC gave a result just above the cut-off and an MDMA concentration of 1 * 1 mg/L by GLC was also just positive. All other samples were clearly positive. Of the twenty negative urines all were below the cut-off level.
Met hylamphetamine N-(4-aminobutyl)amphetamine N-(4-aminobutyl)methylamphetamine
Amphetamine 1 -Methyl-3-propylamine Labetalol Phenethylamine Mrphentermine Phentermine Ephedrine Fenfluramine Phenylpropanolamine Diethylpropion MDMA MDA Adrenaline 100% 140% 50% 20% 18% 17% 4% 40 % 7 % 5 % 12% 7 % 5 % 5 % 2 or0 < 1 %
DISCUSSION
This assay was developed to complement specific assays previously describeds~' and to enable the detection of a broad spectrum of the amphetamine group of drugs. It proved ideal for initial screening of large numbers of urines with any positive samples being confirmed by GLC. Our laboratory normally finds approximately 10% of samples positive for amphetamine or its analogues and the assay provided an efficient, fast and simple system to eliminate negative urines and enable the identification of positive samples by GLC. Forty-six urines found positive by GLC for a wide range of amphetamine analogues produced no false negatives. However, whereas the immunoassays were carried out in approximately 30 min, the GLC technique required an autosampler and an overnight run of 32 h.
Our department has developed more than 30 assays for haptens using fluorescence polarization, and antiserum titres are usually around 1/1OOO. Thus the final dilution of 1/375 in this assay (using the PF120) may seem low. However, most of our assays are developed for use as singlereagents for which early bleeds are the most useful. Later bleeds for this antiserum had titres around 1/800 under the same conditions. Several other assays have been developed using antisera with similar tit re^.^.",^^ The titre depends upon the concentration of tracer used, and when the assay was developed using the Abbott TDx (with a lower tracer concentration) the working titre was 1/800. Similar assays have been developed on the TDx with final antiserum titre as low as 1/400.14 Furthermore, the affinity of antiserum for tracers prepared by attaching fluorescein to small haptens is reduced resulting in lower titres.I5 Higher titres were observed with this antiserum using tracers with a longer bridge (unpublished data).
1-Methyl-3-phenylpropylamine is similar to amphetamine (an extra carbon in the alkyl chain) and forms part of the structure of labetalol (Fig. l ) , a common cross-reactant with broad spectrum antisera. Both had a high crossreactivity (80%-90%) compared with amphetamine. Phenethylamine is found in small quantities in normal urine but would not interfere in the assay at the cut-off levels usually employed. However, it is a product of putrefaction and could interefere with forensic samples.
The suitability of saliva for drug analysis depends primarily on the chemical properties of the drug itself. Lipophilicity and pKa are important and the drug must be able to permeate freely or to be actively excreted into the saliva from the plasma.16 Phentermine, being more lipophilic than phenylpropanolamine, was detectable for 72 h after a single dose (same length of time as in urine) whereas phenylpropanolamine was detectable for only 2 h after the same dose (significantly shorter time than urine). Although this is partly explained by different crossreactivities it would seem to show that saliva could be a valid sample for the detection of abuse of the more lipophilic amphetamines. However, further studies on saliva need to be carried out.
For those interested in the design and development of immunoassays, a close examination of cross reactants relative to molecular structure ( Fig. 1 , Tables 1 and 2) can give an insight into the steric and chemical characteristics important in the recognition and binding of a hapten by antibody.I7~l8 It is important to remember that in this assay the immunogen was developed from amphetamine coupled to the carrier via an N-butylamine bridge. Thus the resulting antibodies were raised against a modified protein, not amphetamine. However, their ability to recognize amphetamine enabled the development of an assay.
Once attached to the carrier protein it is the exposed portion of the hapten molecule that influences the specificity of the resulting antibodies. Charged groups are the most important in terms of specificity19 and for initial attraction into the binding site. The antibody binding site is often described in terms of a groove or cleft.20 If the exposed portion of the hapten contains attractive forces such as charged groups then these can be accommodated deep within the cleft. In our experience such arrangements often result in highly specific a n t i~e r a .~.~~.~~ With the antisera used in this assay, the charged groups determining specificity would be the two secondary amines at either end of the derivative bridge which would be inhibited from deep entry into the cleft by the presence of the exposed phenyl ring. Therefore entry of the hapten, and any cross-reacting molecules, into the cleft is likely to be in a planar direction similar to that described by Pecht.20 Furthermore, the presence of any charged group not complemented in the binding site will reduce binding ability.
Structural modificafions affecting cross reacfivify compared to mefhyl-
Modification
Cross reactivity (TO)
Examole
Conversion to tertiary amine Conversion to primary amine Conversion to propyl side chain Subtraction of a-methyl
In producing the immunogen, the primary amine of amphetamine was converted to a secondary amine with a n alkyl chain, similar to methylamphetamine. As might be expected, the binding site prefers such secondary amines to primary amines (Table l) , as demonstrated by the higher cross-reactivity of methylamphetamine to amphetamine; mephentermine to phentermine; and MDMA to MDA. A similar effect is found with other antisera such as those in earlier Syva (EMIT) kits, where the addition of an alkyl group to amphetamine increased cross-reactivity. ''
Because of the small size of the hapten, the antibody binding-site is likely to accommodate the bridge structure of the immunogen. The increased cross reactivity of N-(4-aminobutyl)amphetamine (140%) compared to methylamphetamine (100%; Table 1 ) supports this view. Fenfluramine with three fluorine atoms in a prominent position on the phenyl ring might be expected to cross-react poorly. However, if binding is in a planar direction, the phenyl ring could rotate freely to position the fluorines to the outside and away from the binding site. Cross-reactivity was higher than expected and supports this view. The oxymethylene group of MDMA would also orient itself to the outside of the binding site but being bulkier and more spatially fixed would disrupt binding to a greater extent. The hydroxyl groups of adrenaline destroy binding altogether as they disrupt the electron cloud, forming dipoles.
Other changes in cross-reactivity are due to alterations to the alkyl region. The additional, uncharged, alpha methyl group of phentermine reduces cross-reactivity, by steric hindrance, whereas the charged 0-hydroxy groups on ephedrine and phenylpropanolamine reduced binding by repulsive electrostatic forces as well as steric effects. Similarly, the ketone group of diethylpropion and the oxymethylene group of MDMA reduced cross-reactivity. In the case of diethylpropion and MDMA, the higher crossreactivity of tertiary and secondary amines to primary amines offsets some of the effects of their charged groups. It has been reported that some monoclonal antibodies supplied by Syva cross-react with chlorpromazine or its metabolites (personal communication). This broad-spectrum antiserum did not cross-react with chlorpromazine nor did it produce false positive results with 10 urines that contained chlorpromazine and its metabolites.
Consideration of the structure of the immunogen used and its likely orientation within any resulting binding-site allows useful predictions about antisera specificity prior to immunization.
